Free Trial

QuidelOrtho (QDEL) Competitors

QuidelOrtho logo
$38.05
-0.94 (-2.41%)
(As of 10/31/2024 ET)

QDEL vs. MYGN, CLDX, VIVO, NTLA, HSKA, MMSI, XRAY, ICUI, HAE, and NEOG

Should you be buying QuidelOrtho stock or one of its competitors? The main competitors of QuidelOrtho include Myriad Genetics (MYGN), Celldex Therapeutics (CLDX), Meridian Bioscience (VIVO), Intellia Therapeutics (NTLA), Heska (HSKA), Merit Medical Systems (MMSI), DENTSPLY SIRONA (XRAY), ICU Medical (ICUI), Haemonetics (HAE), and Neogen (NEOG). These companies are all part of the "medical" sector.

QuidelOrtho vs.

QuidelOrtho (NASDAQ:QDEL) and Myriad Genetics (NASDAQ:MYGN) are both mid-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their earnings, institutional ownership, dividends, analyst recommendations, profitability, valuation, risk, community ranking and media sentiment.

Myriad Genetics received 25 more outperform votes than QuidelOrtho when rated by MarketBeat users. However, 67.33% of users gave QuidelOrtho an outperform vote while only 53.36% of users gave Myriad Genetics an outperform vote.

CompanyUnderperformOutperform
QuidelOrthoOutperform Votes
443
67.33%
Underperform Votes
215
32.67%
Myriad GeneticsOutperform Votes
468
53.36%
Underperform Votes
409
46.64%

QuidelOrtho has a beta of 0.09, indicating that its stock price is 91% less volatile than the S&P 500. Comparatively, Myriad Genetics has a beta of 1.91, indicating that its stock price is 91% more volatile than the S&P 500.

In the previous week, QuidelOrtho and QuidelOrtho both had 4 articles in the media. QuidelOrtho's average media sentiment score of 1.24 beat Myriad Genetics' score of 1.18 indicating that QuidelOrtho is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
QuidelOrtho
1 Very Positive mention(s)
0 Positive mention(s)
2 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Myriad Genetics
1 Very Positive mention(s)
0 Positive mention(s)
2 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

QuidelOrtho presently has a consensus price target of $58.83, indicating a potential upside of 52.14%. Myriad Genetics has a consensus price target of $28.91, indicating a potential upside of 29.99%. Given QuidelOrtho's higher probable upside, equities research analysts plainly believe QuidelOrtho is more favorable than Myriad Genetics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
QuidelOrtho
1 Sell rating(s)
3 Hold rating(s)
3 Buy rating(s)
0 Strong Buy rating(s)
2.29
Myriad Genetics
2 Sell rating(s)
3 Hold rating(s)
7 Buy rating(s)
0 Strong Buy rating(s)
2.42

QuidelOrtho has higher revenue and earnings than Myriad Genetics. Myriad Genetics is trading at a lower price-to-earnings ratio than QuidelOrtho, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
QuidelOrtho$3.00B0.86-$10.10M-$27.79-1.39
Myriad Genetics$753.20M2.68-$263.30M-$1.81-12.30

99.0% of QuidelOrtho shares are held by institutional investors. Comparatively, 99.0% of Myriad Genetics shares are held by institutional investors. 1.0% of QuidelOrtho shares are held by company insiders. Comparatively, 2.1% of Myriad Genetics shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Myriad Genetics has a net margin of -19.35% compared to QuidelOrtho's net margin of -65.60%. QuidelOrtho's return on equity of 3.87% beat Myriad Genetics' return on equity.

Company Net Margins Return on Equity Return on Assets
QuidelOrtho-65.60% 3.87% 2.09%
Myriad Genetics -19.35%-5.64%-3.73%

Summary

Myriad Genetics beats QuidelOrtho on 9 of the 17 factors compared between the two stocks.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

QDEL vs. The Competition

MetricQuidelOrthoDiagnostic substances IndustryMedical SectorNASDAQ Exchange
Market Cap$2.59B$2.63B$5.37B$8.41B
Dividend YieldN/A0.69%5.21%4.20%
P/E Ratio-1.396.35140.7917.72
Price / Sales0.8630.641,454.6778.04
Price / Cash3.5216.4938.9433.56
Price / Book0.513.154.744.59
Net Income-$10.10M$29.98M$115.38M$225.45M
7 Day Performance-0.75%-2.51%-0.54%-0.23%
1 Month Performance-15.57%1.66%3.93%1.90%
1 Year Performance-36.97%0.72%39.33%33.46%

QuidelOrtho Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
QDEL
QuidelOrtho
4.3904 of 5 stars
$38.05
-2.4%
$58.83
+54.6%
-35.2%$2.56B$2.83B-1.377,100Upcoming Earnings
News Coverage
MYGN
Myriad Genetics
4.4915 of 5 stars
$22.26
-2.2%
$28.91
+29.9%
+57.3%$2.02B$753.20M-12.302,700Upcoming Earnings
Positive News
CLDX
Celldex Therapeutics
2.0237 of 5 stars
$25.82
-1.9%
$62.25
+141.1%
+16.0%$1.71B$8.30M-9.42160Upcoming Earnings
Analyst Forecast
VIVO
Meridian Bioscience
1.0451 of 5 stars
$33.97
flat
N/AN/A$1.50B$333.02M35.02702
NTLA
Intellia Therapeutics
4.102 of 5 stars
$14.37
+0.3%
$59.13
+311.5%
-39.9%$1.46B$36.28M-2.62600
HSKA
Heska
N/A$119.99
flat
N/AN/A$1.31B$257.31M-62.17808
MMSI
Merit Medical Systems
4.5638 of 5 stars
$99.12
+4.4%
$103.00
+3.9%
+42.8%$5.76B$1.30B49.566,950Earnings Report
Analyst Forecast
Analyst Revision
News Coverage
Positive News
XRAY
DENTSPLY SIRONA
4.7434 of 5 stars
$23.34
-0.3%
$32.67
+40.0%
-21.9%$4.73B$3.97B-27.1415,000Upcoming Earnings
Analyst Upgrade
Short Interest ↓
ICUI
ICU Medical
4.0565 of 5 stars
$171.75
-2.1%
$170.25
-0.9%
+78.2%$4.18B$2.30B-58.8214,000
HAE
Haemonetics
4.8456 of 5 stars
$71.50
-0.7%
$106.14
+48.5%
-15.2%$3.64B$1.33B32.063,657Upcoming Earnings
NEOG
Neogen
2.5572 of 5 stars
$14.45
-0.8%
$17.50
+21.1%
-3.3%$3.13B$912.20M-131.362,640Positive News

Related Companies and Tools


This page (NASDAQ:QDEL) was last updated on 10/31/2024 by MarketBeat.com Staff
From Our Partners